Edition:
United States

Menlo Therapeutics Inc (MNLO.OQ)

MNLO.OQ on NASDAQ Stock Exchange Global Select Market

8.11USD
19 Jun 2018
Change (% chg)

-- (--)
Prev Close
$8.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
49,698
52-wk High
$38.68
52-wk Low
$6.99

Chart for

About

Menlo Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. It is also evaluating the use of serlopitant for the... (more)

Overall

Beta: --
Market Cap(Mil.): $186.35
Shares Outstanding(Mil.): 22.98
Dividend: --
Yield (%): --

Financials

  MNLO.OQ Industry Sector
P/E (TTM): -- 241.68 34.14
EPS (TTM): -0.63 -- --
ROI: -- -5.91 13.17
ROE: -- -7.75 15.14

BRIEF-Menlo Therapeutics Reports Qtrly Loss Per Share $0.72

* MENLO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Menlo Therapeutics Says Japanese Phase 2 Trial Of Serlopitant Halted

* MENLO THERAPEUTICS - CO'S PARTNERS FOR COMMERCIALIZATION OF SERLOPITANT IN JAPAN, INFORMED DECISION TO HALT JAPANESE PHASE 2 CLINICAL TRIAL OF SERLOPITANT

Apr 24 2018

BRIEF-Menlo Therapeutics Reports Q4 Loss Of $1.80 Per Share

* MENLO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 28 2018

BRIEF-Novo Holdings Reports 5.05 Pct Passive Stake In Menlo Therapeutics

* NOVO HOLDINGS A/S REPORTS 5.05 PERCENT PASSIVE STAKE IN MENLO THERAPEUTICS INC, AS OF JANUARY 29, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2nSBUJu) Further company coverage:

Feb 08 2018

BRIEF-Menlo Therapeutics Now Sees IPO Of 6.5 Mln Shares Of Common Stock Priced Between $16 And $17 Per Share

* MENLO THERAPEUTICS INC NOW SEES IPO OF 6.5 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $16.00 AND $17.00 PER SHARE - SEC FILING

Jan 23 2018

Earnings vs. Estimates